상자성 복합체의 분자량에 따른 T1 및 T2 자기이완시간에 관한 연구 = The Molecular Weight Dependance of Paramagnetic Gd-chelates on T1 and T2 Relaxation Times

국문 초록 (Abstract)

상자성 복합체의 분자량에 따른 물분자의 T1 및 T2 자기이완 특성을 조사해 보고자 하였다. DMF (15 ml)와 DTPA-bis-anhydride (0.71 g, 2 mmol) 용액에 4-aminomethylcyclohexane carboxyilc acid를 넣어 리간드를 합성한 후 $Gd_2O_3$ (0.18g, 0.5 mmol)을 넣어 최종적인 Gd 착화물을 합성하였다. 상자성 복합체의 자기이완율을 측정하기 위해 상자성 복합체를 3차 증류수를 사용하여 1 mM로 희석시켰으며 1.5T(64 MHz)에서 자기이완 시간을 측정하였다. T1 자기이완시간을 측정하기 위하여 반전 회복(Inversion-recovery) 펄스열을 사용하였다. 반전 회복 펄스열의 경우 반전시간(Inversion time, T1)은 50 msec에서부터 최대 1,750 msec까지 총 35개의 반전시간에서 영상을 획득하였다. T2 자기이완시간은 CPMG(Carr-Purcell-Meiboon-Gill) 펄스열을 사용하였다. 자기이완 시간을 구하기 위해 각각의 샘플에 관심영역(region of Interest)을 설정하여 영상의 신호강도를 측정한 후 비선형 곡선 맞춤을 실행하여 T1 및 T2값을 얻어낸 후, 이를 통해서 R1 및 R2를 계산하였다. 분자량이 587 달톤인 Omniscan의 1.5T에서의 T1, T2값이($205.1{\pm}2.57$) msec, ($209.4{\pm}4.28$) msec 임에 비해 새로이 합성된 상자성 Gd 화합물의 경우 모두 T1, T2값이 T1의 경우 분자량에 따라 $(96.35{\pm}2.04)-(79.38{\pm}1.55)$ msec, T2의 경우 $(91.02{\pm}2.08)-(76.66{\pm}1.84)$ msec로 감소한 결과를 얻었다. 새로이 합성된 Gd 화합물 간에도 분자량에 따라 R1 및 R2값이 증가하는 경향을 나타내었다. 상자성 복합체의 분자량이 증가함에 따라 T1 및 T2 자기이완 시간이 단축되고 결과적으로 자기이완율 R1, R2가 분자량에 비례하여 증가하였다.

다국어 초록 (Multilingual Abstract)

To evaluate the T1, T2 magnetic relaxation properties of water molecule according to molecular weight of paramagnetic complex. 4-aminomethyicyclohexane carboxylic acid (0.63 g, 4 mmol) was mixed with the suspension solution of DMF (15 ml) and DTPA-bis-anhydride (0.71 g, 2 mmol) to synthesize the ligand. The ligand was then mixed with $Gd_2O_3$ (0.18 g, 0.5 mmol) to synthesize Gd-chelate. For the measurement of magnetic relaxivity of paramagnetic compounds, the compounds were diluted to 1 mM and then the relaxation times were measured at 1.57 (64 MHz). Inversion-recovery pulse sequence was employed for T1 relaxation measurement and CPMG (Carr-Purcell-Meiboon-Gill) pulse sequence was employed for T2 relaxation measurement. In case of inversion recovery sequence, total 35 images with different inversion time(T1)s ranging from 50 msec to 1,750 msec. To estimate the relaxation times, the signal intensity of each sample was measured using region of Interest (ROI) and then fitted by non-linear least square method to yield T1, T2 relaxation times and also R1 and R2. Compared to T1=($205.1{\pm}2.57$) msec and T2=($209.4{\pm}4.28$) msec of Omniscan (Gadodiamide), which is commercially available paramagnetic MR agent, T1 and T2 values of new paramagnetic complexes were reduced along with their molecular weight. That is, T1 value was ranged from $(96.35{\pm}2.04)\;to\;(79.38{\pm}1.55)$ msec and T2 value was ranged from $(91.02{\pm}2.08)\;to\;(76.66{\pm}1.84)$ msec. Among new paramagnetic complexes, there is a tendency that the R1 and R2 increase as the molecular weight is increases. As molecular weight of paramagnetic complex increases, T1 and T2 relaxation times reduce and thus the increase of relaxivity (R1 and R2) Is proportional to molecular weight.

참고문헌 (Reference)

• 1 Josephson L, "The effects of iron oxides on proton relaxivity" 6 : 647-653, 1988
• 2 Dutta S, "Synthesis and magnetic relaxation properties of paramagnetic Gd-complexes of new DTPA-Bis-Amides. The X-ray crystal structure of [Gd(L)(H2O)]․3H2O (L=DTPA-bis (4-carboxylicphenyl)amide)" 27 (27): 48-, 2006
• 3 Konda SD, "Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts" 12 : 104-113, 2001
• 4 Hustvedt SO, "Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration" 38 : 690-699, 1997
• 5 Misselwitz B, "Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent" 12 : 128-134, 2001
• 6 Enochs WS, "Organ- and Tissue-directed MRI Contrast Agents. In: Clinical Magnetic Resonance Imaging. 2nd ed." Philadelphia 192-220, 1996
• 7 Brasch RC, "New directions in the development of MR imaging contrast media" 183 : 1-11, 1992
• 8 Winter PM, "Molecular imaging of angiogenesis in early- stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles" 108 : 2270-2274, 2003
• 9 Lauffer RB, "Magnetic resonance contrast media: principles and progress" 6 : 65-84, 1990
• 10 Sibson NR, "MRI detection of early endothelial activation in brain inflammation" 51 : 248-252, 2004
• 11 Sipkins DA, "ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imagingICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging" 104 : 1-9, 2000
• 12 Knopp MV, "Contrast agents for MRA: future directions" 10 : 314-316, 1999
• 13 Mahfouz AE, "Contrast agents" 5 : 223-240, 1997
• 14 Watson AD, "Contrast Agents. In: Stark DD, Bradley WG, eds. Magnetic Resonance Imaging. 2nd ed." Mosby-Year Book, St. Louis 372-437, 1992
• 15 Weinmann H, "A new lipophilic Gadolinium chelate as a tissue specific contrast medium for MRI" 22 : 233-237, 1991